In contrast to the hormonal or HER2 (human epidermal growth factor receptor) positive BC, the specific molecular pathophysiology of TN BC remains poorly understood, resulting in a lack of efficient target therapies [3]. This evidence concerns the gene ERBB2 and breast cancer.